Iohexol Imax (Iohexol)

Iohexol contains a high concentration of iodine atoms, which strongly absorb X‑ray photons. After injection, the iodine distributes within the bloodstream and extracellular space, raising the radiodensity of blood and tissues. This contrast difference allows imaging equipment to differentiate structures more distinctly, producing high‑resolution diagnostic images.

The dose of Iohexol Imax is determined by the prescribing clinician based on the specific imaging study, patient weight, age, and renal function. Dosage calculations follow established radiology guidelines and are individualized for each procedure; no fixed regimen can be stated without a medical order.

Safety data for Iohexol Imax during pregnancy and lactation are limited. It should be used only when the expected diagnostic benefit outweighs potential risks to the fetus or infant. Clinicians must evaluate each case carefully and discuss possible concerns with the patient.

To order Iohexol Imax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Iohexol Imax is a non‑ionic, low‑osmolality iodinated contrast agent, offering a favorable safety profile compared with older high‑osmolality agents. Compared with other modern agents such as iopamidol or ioversol, Iohexol provides similar image quality while maintaining low rates of discomfort and adverse reactions, though specific choice may depend on institutional protocols and patient factors.

Iohexol Imax should be stored at ambient temperature, protected from light and moisture, and kept in its original packaging. The product must not be frozen or shaken vigorously. Follow the manufacturer’s label for any additional handling instructions to preserve sterility and efficacy.

Iohexol Imax is administered as a sterile solution for injection by qualified healthcare professionals. It is delivered intravenously or intra‑arterially, typically through a power injector or manual bolus, depending on the imaging protocol. Administration is performed in a controlled clinical setting with appropriate monitoring.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, contrast‑induced nephropathy leading to acute renal impairment, and cardiovascular events like hypotension or arrhythmia. Prompt recognition and management of these reactions are essential, and patients at higher risk should be closely monitored.

Iohexol Imax should be avoided in patients with a known severe allergy to iodinated contrast media, uncontrolled hyperthyroidism, or severe renal insufficiency (e.g., eGFR <30 mL/min/1.73 m²) unless the diagnostic benefit justifies the risk. Clinicians must assess individual contraindications before administration.